![]() |
Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with
Seo Yun Kim, Jae Kyung Myung, Hye-Ryoun Kim, Im Il Na, Jae Soo Koh, Hee Jong Baek, Cheol Hyeon Kim
Tuberc Respir Dis. 2019;82(1):62-70. Published online 2018 Jun 19 DOI: https://doi.org/10.4046/trd.2018.0004
|
Citations to this article as recorded by
EGFR-Tyrosine Kinase Inhibitor Retreatment in Non-Small-Cell Lung Cancer Patients Previously Exposed to EGFR-TKI: A Systematic Review and Meta-Analysis
Isabella Michelon, Maysa Vilbert, Caio Ernesto do Rego Castro, Carlos Stecca, Maria Inez Dacoregio, Manglio Rizzo, Vladmir Cláudio Cordeiro de Lima, Ludimila Cavalcante
Journal of Personalized Medicine.2024; 14(7): 752. CrossRef Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
Ni Putu Ayu Widiasari, Ida Bagus Ngurah Rai, Ida Ayu Jasminarti Dwi Kusumawardani, I Gede Ketut Sajinadiyasa, Ni Wayan Candrawati, Ni Luh Putu Eka Arisanti
Romanian Journal of Internal Medicine.2023; 61(1): 63. CrossRef New Targeted Therapy for Non-Small Cell Lung Cancer
Eun Ki Chung, Seung Hyun Yong, Eun Hye Lee, Eun Young Kim, Yoon Soo Chang, Sang Hoon Lee
Tuberculosis and Respiratory Diseases.2023; 86(1): 1. CrossRef Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
Boyeon Kim, Young Soo Park, Jae Sook Sung, Jong Won Lee, Saet Byeol Lee, Yeul Hong Kim
Cancer Medicine.2021; 10(1): 372. CrossRef Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
Yong-Jin Kim, Mark Oremus, Helen H Chen, Thomas McFarlane, Danielle Fearon, Susan Horton
Journal of Comparative Effectiveness Research.2021; 10(3): 193. CrossRef Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
Yong-Jin Kim, Mark Oremus, Helen H. Chen, Thomas McFarlane, Danielle Fearon, Susan Horton
PharmacoEconomics.2021; 39(5): 537. CrossRef A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma
Kazuya Takakuwa, Kaoru Mogushi, Min Han, Tomoaki Fujii, Masaki Hosoya, Arina Yamanami, Tomomi Akita, Chikamasa Yamashita, Tetsu Hayashida, Shunsuke Kato, Shigeo Yamaguchi
Scientific Reports.2020;[Epub] CrossRef Curcumin Suppresses Epithelial Growth Factor Receptor (EGFR) and Proliferative Protein (Ki 67) in Acute Lung Injury and Lung Fibrosis In vitro and In vivo
Sadiya Bi Shaikh, Ashwini Prabhu, Yashodhar Prabhakar Bhandary
Endocrine, Metabolic & Immune Disorders - Drug Targets.2020; 20(4): 558. CrossRef Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer
Chao Tu, Yingqi Pi, Shan Xing, Yang Ling, Rama Krishna Kancha
PLOS ONE.2020; 15(10): e0240633. CrossRef
|